Company Overview: Moleculin

Industry News

3 Oct

Moleculin Signs Agreement with First Hospital for Annamycin Trials

HOUSTON, TX–(Marketwired – October 03, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced...

Read more

26 Sep

Moleculin Announces FDA Approval of Annamycin IND

HOUSTON, TX–(Marketwired – September 26, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced...

Read more

13 Sep

Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma

HOUSTON, TX–(Marketwired – September 13, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

6 Sep

Moleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roche’s Drug Avastin

HOUSTON, TX–(Marketwired – September 06, 2017) – Moleculin Biotech, Inc. (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

29 Aug

Moleculin Announces Filing with FDA of IND for its Leukemia Drug Annamycin

HOUSTON, TX–(Marketwired – August 29, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

9 Aug

Moleculin Comments on Recent FDA Drug Approvals for Acute Myeloid Leukemia

HOUSTON, TX–(Marketwired – August 09, 2017) – Moleculin Biotech, Inc., (MBRX) (“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today commented on...

Read more

3 Aug

Moleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO

HOUSTON, TX–(Marketwired – August 03, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced it...

Read more

27 Jul

Moleculin Strengthens Board of Directors with Appointment of John M. Climaco

HOUSTON, TX–(Marketwired – July 27, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the...

Read more

25 Jul

Moleculin’s New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center

HOUSTON, TX–(Marketwired – July 25, 2017) – Moleculin Biotech, Inc., (MBRX)(“Moleculin” or the “Company”), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address